Jana Ambrožič1, Marta Cvijič2, Mojca Bervar2, Špela Mušič3, Matjaž Bunc2. 1. Clinical Department of Cardiology, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia. jana.ambrozic@gmail.com. 2. Clinical Department of Cardiology, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia. 3. Clinical Department of Anesthesiology and Perioperative Intensive Therapy, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia.
Abstract
BACKGROUND: MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure. METHODS: We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017. RESULTS: Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3-15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect. CONCLUSION: Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.
BACKGROUND: MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure. METHODS: We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017. RESULTS: Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3-15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect. CONCLUSION: Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.
Authors: Christian Hamilton-Craig; Wendy Strugnell; Niranjan Gaikwad; Matthew Ischenko; Vicki Speranza; Jonathan Chan; Johanne Neill; David Platts; Gregory M Scalia; Darryl J Burstow; Darren L Walters Journal: Ann Cardiothorac Surg Date: 2015-07
Authors: Paul A Grayburn; Elyse Foster; Chithra Sangli; Neil J Weissman; Joseph Massaro; Donald G Glower; Ted Feldman; Laura Mauri Journal: Circulation Date: 2013-09-06 Impact factor: 29.690
Authors: Thomas Smith; Patrick McGinty; William Bommer; Reginald I Low; Scott Lim; Peter Fail; Jason H Rogers Journal: Catheter Cardiovasc Interv Date: 2012-03-15 Impact factor: 2.692
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Felix Kreidel; Christian Frerker; Michael Schlüter; Hannes Alessandrini; Thomas Thielsen; Stephan Geidel; Ulrich Schäfer; Karl-Heinz Kuck Journal: JACC Cardiovasc Interv Date: 2015-09 Impact factor: 11.195
Authors: Laura Mauri; Elyse Foster; Donald D Glower; Patricia Apruzzese; Joseph M Massaro; Howard C Herrmann; James Hermiller; William Gray; Andrew Wang; Wesley R Pedersen; Tanvir Bajwa; John Lasala; Reginald Low; Paul Grayburn; Ted Feldman Journal: J Am Coll Cardiol Date: 2013-05-09 Impact factor: 24.094